Induction of corticostriatal LTP by 3-nitropropionic acid requires the activation of mGluR1/PKC pathway

Neuropharmacology

Volumn 46, Issue 6, 2004, Pages 761-769

  Gubellini, Paolo ^a,b   Centonze, Diego ^b   Tropepi, Domenicantonio ^b   Bernardi, Giorgio ^b   Calabresi, Paolo ^b  

^a CNRS   (France)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Electrophysiology; Glutamate; Huntington's disease; LY 367385; MPEP; Succinate dehydrogenase; Synaptic plasticity

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; 3 NITROPROPIONIC ACID; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; BICUCULLINE; CALPHOSTIN C; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; PROTEIN KINASE C; STAUROSPORINE; SUCCINATE DEHYDROGENASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVATION; LONG TERM POTENTIATION; MALE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; ENZYME INHIBITORS; LONG-TERM POTENTIATION; MALE; NITRO COMPOUNDS; PROPIONIC ACIDS; PROTEIN KINASE C; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 1642277124     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.11.021     Document Type: Article

References (76)

1. Alexi T., Hughes P.E., Knusel B., Tobin A.J. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Experimental Neurology. 153:1998;74-93.
2. Battaglia G., Bruno V., Pisani A., Centonze D., Catania M.V., Calabresi P., Nicoletti F. Selective blockade of type-1 metabotropic glutamate receptors induces neuroprotection by enhancing GABAergic transmission. Molecular and Cellular Neuroscience. 17:2001;1071-1083.
3. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Journal of Neuroscience. 10:1993;4181-4192.
4. Beal M.F., Ferrante R.J., Henshaw R., Matthews R.T., Chan P.H., Kowall N.W., Epstein C.J., Schulz J.B. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. Journal of Neurochemistry. 65:1995;919-922.
5. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz J.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
6. Benquet P., Gee C.E., Gerber U. Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. Journal of Neuroscience. 22:2002;9679-9686.
7. Berridge M.J. Neuronal calcium signaling. Neuron. 21:1998;13-26.
8. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proceedings of National Academy of Sciences USA. 92:1995;7105-7109.
9. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M.K., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Annals of Neurology. 41:1997;646-653.
10. Bruno V., Battaglia G., Kingston A., O'Neill M.J., Catania M.V., Di Grezia R., Nicoletti F. Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors. Neuropharmacology. 38:1999;199-207.
11. Bruno V., Copani A., Knopfel T., Kuhn R., Casabona G., Dell'Albani P., Condorelli D.F., Nicoletti F. Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced degeneration in cultured cortical cells. Neuropharmacology. 34:1995;1089-1098.
12. Buisson A., Choi D.W. The inhibitory mGluR agonist S-4-carboxy-3-hydroxy- phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death. Neuropharmacology. 35:1995;1081-1087.
13. Calabresi P., Centonze D., Gubellini P., Pisani A., Bernardi G. Endogenous ACh enhances striatal NMDA-responses via M1-like muscarinic receptors and PKC activation. European Journal of Neuroscience. 10:1998;2887-2895.
14. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Progress in Neurobiology. 61:2000;231-265.
15. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G.A., Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: implications for ischemia and Huntington's disease. Annals of Neurology. 43:1998;586-597.
16. Calabresi P., De Murtas M., Bernardi G. The neostriatum beyond the motor function: experimental and clinical evidence. Neuroscience. 78:1997;39-60.
17. Calabresi P., Gubellini P., Centonze D., Picconi B., Bernardi G., Chergui K., Svenningsson P., Fienberg A.A., Greengard P. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. Journal of Neuroscience. 20:2000;8443-8451.
18. Calabresi P., Gubellini P., Picconi B., Centonze D., Pisani A., Bonsi P., Greengard P., Hipskind R.A., Borrelli E., Bernardi G. Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. Journal of Neuroscience. 21:2001;5110-5220.
19. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent blockade of NMDA receptor channel. European Journal of Neuroscience. 4:1992;929-935.
20. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. Post-receptor mechanisms underlying striatal long-term depression. Journal of Neuroscience. 14:1994;4871-4881.
21. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends in Neuroscience. 19:1996;19-24.
22. Calabresi P., Saulle E., Marfia G.A., Centonze D., Mulloy R., Picconi B., Hipskind R.A., Conquet F., Bernardi G. Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum. Molecular Pharmacology. 60:2001;808-815.
23. Cha J.J., Talati A., Kerner A.J., Lichtenbaum A.R., Young A.B. Antisense oligodeoxynucleotide direct against mGluR5 glutamate receptor protect agains malonic acid lesions in rat striatum. Neuropharmacology. 35:1996;A7.
24. Conn J.P., Pin J.P. Pharmacology and function of metabotropic glutamate receptors. Annual Reviews in Pharmacology and Toxicology. 37:1997;205-237.
25. Cozzi A., Meli E., Carla V., Pellicciari R., Moroni F., Pellegrini-Giampietro D.E. Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity? Neuropharmacology. 43:2002;119-130.
26. Erecinska M., Nelson D. Effects of 3-nitropropionic acid on synaptosomal energy and transmitter metabolism: relevance to neurodegenerative brain diseases. Journal of Neurochemistry. 63:1994;1033-1041.
27. Ferraguti F., Baldani-Guerra B., Corsi M., Nakanishi S., Corti C. Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. European Journal of Neuroscience. 11:1999;2073-2082.
28. Ferrante R.J., Kowall N.J., Beal M.F., Richardson E.P., Martin J.B. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 320:1985;561-563.
29. Ghosh A., Greenberg M.E. Calcium signaling in neurons: molecular mechanisms and cellular consequences. Science. 268:1995;239-247.
30. Greene J.G., Greenamyre J.T. Bioenergetics and glutamate excitotoxicity. Progress in Neurobiology. 48:1996;613-634.
31. Greene J.G., Porter R.H., Eller R.V., Greenamyre J.T. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. Journal of Neurochemistry. 61:1993;1151-1154.
32. Greene J.G., Sheu S.-S., Gross R.A., Greenamyre J.T. 3-Nitropropionic acid exacerbates N-methyl-d-aspartate toxicity in striatal culture by multiple mechanisms. Neuroscience. 84:1998;503-510.
33. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Annals of Neurology. 39:1996;385-389.
34. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agrò A., Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. Journal of Neuroscience. 22:2002;6900-6907.
35. Gubellini P., Saulle E., Centonze D., Costa C., Tropepi D., Bernardi G., Conquet F., Calabresi P. Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology. 44:2003;8-16.
36. Hashimoto T., Kitamura N., Saito N., Komure O., Nishino N., Tanaka C. The loss of beta II-protein kinase C in the striatum from patients with Huntington's disease. Brain Research. 585:1992;303-306.
37. Hidaka H., Kobayashi R. Pharmacology of protein kinase inhibitors. Annual Review in Pharmacology and Toxicology. 32:1992;377-397.
38. Jakel R.J., Maragos W.F. Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends in Neuroscience. 23:2000;239-245.
39. Karim F., Wang C.C., Gereau R.W. VI. Metabotropic glutamate receptor subtypes 1 and 5 are activators of extracellular signal-regulated kinase signaling required for inflammatory pain in mice. Journal of Neuroscience. 21:2001;3771-3779.
40. Kim G.W., Copin J.C., Kawase M., Chen S.F., Sato S., Gobbel G.T., Chan P.H. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. Journal of Cerebral Blood Flow and Metabolism. 20:2000;119-129.
41. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C, (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochemical and Biophysical Research Communications. 159:1989;548-553.
42. LaFontaine M.A., Geddes J.W., Banks A., Butterfield D.A. 3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Research. 858:2000;356-362.
43. Lastres-Becker I., De Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernandez-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry. 84:2003;1097-1109.
44. Lastres-Becker I., Hansen H.H., Berrendero F., De Miguel R., Perez-Rosado A., Manzanares J., Ramos J.A., Fernandez-Ruiz J. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse. 44:2002;23-35.
45. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid - exogenous animal neurotoxin and possible human striatal toxin. Canadian Journal of Neurological Sciences. 18:1991;492-498.
46. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. Journal of Nutrition. 130:2000;1007S-1015S.
47. Mitchell I.J., Cooper A.J., Griffitths M.R. The selective vulnerability of striatopallidal neurons. Progress in Neurobiology. 59:1999;691-719.
48. Murphy A.N., Fiskum G., Beal M.F. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. Journal of Cerebral Blood Flow and Metabolism. 19:1999;231-245.
49. 2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochemical International. 43:2003;89-99.
50. Nicoletti F., Bruno V., Catania V., Battaglia G., Copani A., Barbagallo G., Cena V., Sanchez-Prieto J., Spano P.F., Pizzi M. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection. Neuropharmacology. 38:1999;1477-1484.
51. Orlando L.R., Standaert D.G., Penney J.B., Young A.B. Metabotropic receptors in excitotoxicity: (S)-4-carboxy-3-hydroxy-phenyl-glycyne ((S)-4C3HPG) protects against rat striatal quinolinic acid lesions. Neuroscience Letters. 202:1995;109-112.
52. Palfi S., Ferrante R.J., Brouillet E., Beal M.F., Dolan R., Guyot M.C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. Journal of Neuroscience. 16:1996;3019-3025.
53. Pang Z., Bondada V., Sengoku T., Siman R., Geddes J.W. Calpain facilitates the neuron death induced by 3-nitropropionic acid and contributes to the necrotic morphology. Journal of Neuropathology and Experimental Neurology. 62:2003;633-643.
54. Pang Z., Geddes J.W. Mechanisms of cell death induced by the mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis and delayed apoptosis. Journal of Neuroscience. 17:1997;3064-3073.
55. Peavy R.D., Conn P.J. Phosphorylation of mitogen-activated protein kinase in cultured rat cortical glia by stimulation of metabotropic glutamate receptors. Journal of Neurochemistry. 71:1998;603-612.
56. Pellegrini-Giampietro D.E., Peruginelli F., Meli E., Cozzi A., Albani-Torregrossa S., Pellicciari R., Moroni F. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time-course and mechanisms. Neuropharmacology. 38:1999;1607-1619.
57. Pin J.-P., Acher F. The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Current Drug Targets - CNS and Neurological Disorders. 1:2002;297-317.
58. Pin J.-P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26.
59. Pisani A., Calabresi P., Centonze D., Bernardi G. Enhancement of NMDA responses by group I metabotropic receptor activation in striatal neurons. British Journal of Pharmacology. 120:1997;1007-1014.
60. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience. 106:2001;579-587.
61. Price D.L., Sisodia S.S., Borchelt D.R. Genetic neurodegenerative diseases: the human illness and transgenic models. Science. 282:1998;1079-1083.
62. Reddy P.H., Williams M., Tangle D.A. Recent advances in understanding the pathogenesis of Huntington's disease. Trends in Neuroscience. 22:1999;248-255.
63. Reynolds D.S., Carter R.J., Morton A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. Journal of Neuroscience. 18:1998;10116-10127.
64. Reynolds N.C. Jr, Lin W., Meyer Cameron C., Roerig D.L. Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat. Brain Research. 778:1997;140-149.
65. Sato S., Gobbel G.T., Honkaniemi J., Li Y., Kondo T., Murakami K., Sato M., Copin J.C., Chan P.H. Apoptosis in the striatum of rats following intraperitoneal injection of 3-nitropropionic acid. Brain Research. 745:1997;343-347.
66. Sato S., Gobbel G.T., Honkaniemi J., Li Y., Kondo T., Murakami K., Sato M., Copin J.C., Sharp F.R., Chan P.H. Decreased expression of bcl-2 and bcl-x mRNA coincides with apoptosis following intracerebral administration of 3-nitropropionic acid. Brain Research. 808:1998;56-64.
67. Schinkmann K.A., Kim T.A., Avraham S. Glutamate-stimulated activation of DNA synthesis via mitogen-activated protein kinase in primary astrocytes: involvement of protein kinase C and related adhesion focal tyrosine kinase. Journal of Neurochemistry. 74:2000;1931-1940.
68. Schoepp D.D., Conn P.J. Metabotropic glutamate receptors in brain function and pathology. Trends in Pharmacological Science. 14:1993;13-20.
69. Stern E.A., Jaeger D., Wilson C.J. Membrane potential synchrony of simultaneously recorded striatal spiny neurons in vivo. Nature. 394:1998;475-478.
70. Strasser U., Lobner D., Behrens M.M., Canzoniero L.M., Choi D.W. Antagonists for group I mGluRs attenuate excitotoxic neuronal death in cortical cultures. European Journal of Neuroscience. 10:1998;2848-2855.
71. Sugino T., Nozaki K., Tokime T., Hashimoto N., Kikuchi H. 3-nitropropionic acid induces poly(ADP-ribosyl)ation and apoptosis related gene expression in the striatum in vivo. Neuroscience Letters. 237:1997;121-124.
72. Thandi S., Blank J.L., Challiss R.A. Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signaling pathways. Journal of Neurochemistry. 83:2002;1139-1153.
73. Wilkinson S.E., Parker P.J., Nixon J.S. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochemical Journal. 294:1993;335-337.
74. Wullner U., Young A.B., Penney J.B., Beal M.F. 3-Nitropropionic acid toxicity in the striatum. Journal of Neurochemistry. 63:1994;1772-1781.
75. Xia Z., Dudek H., Miranti C.K., Greenberg M.E. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. Journal of Neuroscience. 16:1996;5425-5436.
76. Yan Z., Feng J., Fienberg A.A., Greengard P. D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. Proceedings of the National Academy of Science USA. 96:1999;11607-11612.